Claims for Patent: 8,293,752

Summary for Patent: 8,293,752

Title:	Compounds useful as Raf kinase inhibitors
Abstract:	The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.
Inventor(s):	Weirong Chen, Jennifer Cossrow, Lloyd Franklin, Bing Guan, John Howard Jones, Gnanasambandam Kumaravel, Benjamin Lane, Adam Littke, Alexey Lugovskoy, Hairuo Peng, Noel Powell, Brian C. Raimundo, Hiroko Tanaka, Jeffrey Vessels, Thomas Wynn, Zhili Xin
Assignee:	Xoma US LLC, Day One Biopharmaceuticals Inc
Application Number:	US12/164,762
Patent Claims:	1. A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: Cy1 is an optionally substituted 5 membered-aromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Cy2 is an optionally substituted 6 membered aromatic ring having 1-2 heteroatoms, independently selected from nitrogen, oxygen, and sulfur; L1 is an optionally substituted, straight or branched C1-6 alkylene chain; L2 is —C(O)N(R)—; each R is independently hydrogen or an optionally substituted C1-6 aliphatic group; R1 is hydrogen or an optionally substituted C1-6 aliphatic group; each of Rx and Ry is independently selected from -halo, or —N(R2)2; and each R2 is independently hydrogen or an optionally substituted C1-6 aliphatic group. 2. The compound according to claim 1, wherein Ry is —N(R2)2. 3. The compound according to claim 2, wherein Ry is —NH2, —NHCH3, —NHCH2CH3, —NHCH2CH2CH3, —NHCH(CH3)2, —NH(C3H5), —NHCH2CH2CH2OH, or —NHCH2CH2CH2NH(CH3)2. 4. The compound according to claim 1, wherein R1 is hydrogen and L1 is an optionally substituted, straight or branched C1-4 alkylene chain. 5. The compound according claim 1, wherein Cy1 is an optionally substituted pyrrolyl, pyrazolyl, imidazolyl, triazolyl, thiophenyl, furanyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, or oxadiazolyl group. 6. The compound according to claim 1, wherein L2 is —C(O)N(H)—. 7. The compound according to claim 1, wherein Cy2 is an optionally substituted group selected from pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl. 8. The compound according to claim 1, wherein said compound is of formula II: or a pharmaceutically acceptable salt thereof. 9. The compound according to claim 8, wherein said compound of formula II is of formula II-a or II-b: or a pharmaceutically acceptable salt thereof. 10. A pharmaceutical composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier, adjuvant, or vehicle. 11. The composition of claim 10, in combination with a therapeutic agent selected from a chemotherapeutic or anti-proliferative agent, an anti-inflammatory agent, an immunomodulatory agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating destructive bone disorders, an agent for treating liver disease, an anti-viral agent, an agent for treating blood disorders, an agent for treating diabetes, and an agent for treating immunodeficiency disorders. 12. The compound according to claim 1, wherein the compound is: or a pharmaceutically acceptable salt thereof. 13. A pharmaceutical composition comprising the compound of claim 12, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.